Full-Time
Senior National Account Manager
Grocery, Consumer
Updated on 9/3/2026
Galderma
1,001-5,000 employees
Independent dermatology company delivering skincare therapies
No salary listed
London, UK
Hybrid
Hybrid role based in London.
Bachelor's
 Sales & Account Management (1) |
|---|
Get referred to Galderma
See people who can refer or advise you
- Degree-level education is required.
- Commercial experience in fast-moving consumer goods sales, including the ability to analyze and interpret data and manage multiple joint business plans, is required.
- Excellent United Kingdom customer and fast-moving consumer goods market knowledge is required.
- Strong planning skills and the ability to work autonomously are required.
- Commercial acumen, negotiation skills, and relationship-building ability are required.
- The ability to listen and interact effectively with different interpersonal styles and communicate clearly and concisely is required.
- Knowledge of the beauty industry and current industry trends and innovation is required.
- Build bottom-up customer account plans aligned with Consumer Business Unit objectives and customer strategies.
- Sell, negotiate, monitor, and deliver execution to achieve long-term category growth and profitable market-share increases.
- Build productive business relationships with cross-functional stakeholders within customers.
- Achieve net sales and gross-to-net percentage targets and collaboratively manage other profit-and-loss lines affected or influenced by sales.
- Define account-specific strategies, plans, and tactics that deliver category growth based on consumer, shopper, and customer requirements.
- Ensure multifunctional input and alignment on key growth opportunities and account plans.
- Execute the in-store vision of success for the category in each customer and continuously review the effectiveness of in-store actions.
- Execute promotional guidelines by category and channel and evaluate return on investment of trade investments, amending the in-year plan where necessary.
- Develop customer-focused commercial propositions that support annual brand-plan strategies.
- Maintain current knowledge of the marketplace, brands, and customers to provide effective market intelligence.
- Adhere to company principles and policies, including local sales policy, local trade terms, safety, and legal regulations.
- Commercial education, such as business, economics, or administration, is preferred.
- Skincare experience is a plus.
Dermatology-focused medicines and skincare products are Galderma’s core business, including prescription therapies, over-the-counter skincare, and injectable aesthetics. It combines pharmaceutical R&D with consumer skin insights to develop treatments that address skin conditions, improve appearance, and support overall skin health. Unlike many peers, Galderma operates as an independent, publicly traded dermatology specialist with a long history in skin science, spanning prescription, OTC, and aesthetic segments. Its goal is to be a global leader in science-based solutions for skin conditions, growing across therapeutic dermatology, injectables, and skincare worldwide.
Company Size
1,001-5,000
Company Stage
Private
Total Funding
$5.7B
Headquarters
Lausanne, Switzerland
Founded
1981
Get referred to Galderma
See people who can refer or advise you
Simplify's Take
What believers are saying
- H1 2026 net sales hit $3.134 billion, up 24.6%, and guidance rose.
- Nemluvio generated $433 million in H1 2026, with U.S. starts leading prurigo nodularis.
- Galderma opened its Miami headquarters August 24, 2026, supporting U.S. growth and hiring.
What critics are saying
- The FDA rejected Relfydess again on July 1, 2026, delaying U.S. Botox competition.
- AbbVie's Allergan Aesthetics still dominates injectables, limiting Galderma's share gains before 2028.
- Nemluvio faces Sanofi's Dupixent and Lilly's Ebglyss in crowded eczema markets.
What makes Galderma unique
- Galderma is the only pure-play dermatology company, spanning aesthetics, skincare, therapeutics.
- It owns globally recognized brands: Cetaphil, Alastin, Dysport, Restylane, Sculptra, Nemluvio.
- Its ready-to-use Relfydess platform differentiates by injection convenience and faster onset.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Flexible Work Hours
Growth & Insights and Company News
6 month growth
↓ -1%1 year growth
↓ -1%2 year growth
↓ -1%Galderma's $650 million bet on U.S. manufacturing captures Europe's new investment playbook | Fortune. Good morning. The English are coming. So are the Dutch, Germans, Danish, Swiss and other Europeans driving growth in foreign direct investment in the U.S. right now. FDI rose by $266 billion to $5.86 trillion at the end of 2025, with Europe accounting for much of the increase and manufacturing remaining the largest target. V3 Media know why it's happening: Companies want access to the world's deepest consumer market and pool of capital, along with U.S. talent - and, of course, manufacturing on American soil is a hedge against tariffs. It's good news for policymakers looking for tangible wins. Several European CEOs have told me their goal is to build deeply-rooted American businesses. Galderma is a case in point. The Swiss dermatology company, whose brands range from Cetaphil and Alastin to injectable fillers such as Sculptra and Restylane, generated $5.24 billion in revenue last year. The U.S. accounted for 40% of those sales and is its fastest-growing market. Galderma announced last year that it will invest more than $650 million in U.S. manufacturing through 2030. "If you want to succeed, you have to succeed in the U.S.," CEO Flemming Ørnskov told me. Ørnskov's first priority was access to R&D talent. "The business was in Fort Worth, and I said, 'If we want to be competing against Sanofi and everybody else, let's move it to Boston.'" (The French drugmaker Sanofi's Dupixent competes with Galderma's Nemluvio in treating skin conditions such as eczema.) Galderma's big competitive target is AbbVie-owned Allergan Aesthetics, the U.S. injectables leader that makes Botox and Juvéderm. "Until we have closed the gap to Allergan in market share, I won't think we've succeeded,"said Ørnskov. That's why geography matters: For Galderma's U.S. headquarters, he picked Miami because it serves a fast-growing consumer market and is a gateway to Latin America. He's also building a presence in Orange County, Calif., because, he says, "the aesthetic business is dependent on expertise and that expertise is so concentrated there." Fort Worth remains an important distribution hub. Of course, there are also some challenges for companies seeking a foothold in the U.S., Ørnskov said: "The bar for aesthetic products approval is the highest in the U.S. - by far the highest - and it's become even tougher... but it's such an important market that we have to do whatever it takes." Contact CEO Daily via Diane Brady at [email protected] Top leadership news. Do CEOs actually matter? The Pulitzer Prize-winner author of Guns, Germs, and Steel examines that question in his forthcoming book. In an excerpt from Profits, Prophets, Coaches, and Kings, Jared Diamond explains that CEOs have more discretion in certain industries, such as computers, soap and perfume, games and toys, motion pictures, and clothing for young people. But CEOs have less discretion in public utilities, steel, shipbuilding, railways, and gas transmission. OpenAI limits access to Astra's top cyber tools OpenAI's Astra is substantially more capable than its current frontier AI model, GPT-5.6 Sol, which itself is highly capable at cyber tasks. But only a handful of partners will get access to its most advanced cybersecurity capabilities as OpenAI works to balance helping companies prevent cyberattacks while not empowering attackers at the same time. New bill would tax AI tokens to fund jobs A new House proposal would impose an excise tax on major AI companies and automatically increase the levy if unemployment climbs, funneling the money into creating jobs in areas from housing construction and infrastructure to child and elder care. The bill proposes a bifurcated taxation: either tax the value of the tokens or tax revenue from AI services and certain transactions with affiliated companies, whichever yields the higher sum. The markets. S&P 500 futures are down 0.25% this morning. The STOXX Europe 600 was down 0.63% in early trading. The U.K.'s FTSE 100 was down 0.52% in early trading. The Nikkei 225 wasdown 2.85%. South Korea's KOSPI wasdown 3.99%. China's CSI 300 was down 1.38%. Hong Kong's Hang Seng was down 0.07%. India's NIFTY 50 was down 0.72%. Bitcoin is down at $77k. Around the watercooler. The Pentagon is giving 3 million military and civilian workers access to ChatGPT and Grok through a secure AI platform built for 'warfighter needs' by Marco Quiroz-Gutierrez IKEA is spending $1.4 billion to cut prices, joining Walmart and Target in a race to win back shoppers by Mia Osmonbekov Once a champion for physical media, Sony is now telling PlayStation customers they don't actually own the digital video games they paid $70 for by Sasha Rogelberg As Gen Z flocks back to accounting, EY is investing $100 million in bonuses for employees who prove they have human skills by Preston Fore From a Singapore airport soundtrack to new AI-powered PCs, HP is looking for a new rhythm in Asia by Angelica Ang CEO Daily is curated and edited by Joseph Abrams, Jason Ma, Claire Zillman, and Lee Clifford.
Galderma's $650M bet on US manufacturing captures Europe's new investment playbook. Good morning. The English are coming. So are the Dutch, Germans, Danish, Swiss and different Europeans driving development in overseas direct funding within the U.S. proper now. FDI rose by $266 billion to $5.86 trillion on the finish of 2025, with Europe accounting for a lot of the rise and manufacturing remaining the most important goal. We all know why it's occurring: Corporations need entry to the world's deepest client market and pool of capital, together with U.S. expertise - and, after all, manufacturing on American soil is a hedge in opposition to tariffs. It's excellent news for policymakers on the lookout for tangible wins. A number of European CEOs have advised me their objective is to construct deeply-rooted American companies. Galderma is a living proof. The Swiss dermatology firm, whose manufacturers vary from Cetaphil and Alastin to injectable fillers resembling Sculptra and Restylane, generated $5.24 billion in income final yr. The U.S. accounted for 40% of these gross sales and is its fastest-growing market. Galderma introduced final yr that it'll make investments greater than $650 million in U.S. manufacturing by 2030. "If you wish to succeed, you must succeed within the U.S.," CEO Flemming Ørnskov advised me. Ørnskov's first precedence was entry to R&D expertise. "The enterprise was in Fort Value, and I mentioned, 'If we need to be competing in opposition to Sanofi and all people else, let's transfer it to Boston.'" (The French drugmaker Sanofi's Dupixent competes with Galderma's Nemluvio in treating pores and skin situations resembling eczema.) Galderma's large aggressive goal is AbbVie-owned Allergan Aesthetics, the U.S. injectables chief that makes Botox and Juvéderm. "Till now we have closed the hole to Allergan in market share, I gained't suppose we've succeeded," mentioned Ørnskov. That's why geography issues: For Galderma's U.S. headquarters, he picked Miami as a result of it serves a fast-growing client market and is a gateway to Latin America. He's additionally constructing a presence in Orange County, Calif., as a result of, he says, "the aesthetic enterprise depends on experience and that experience is so concentrated there." Fort Value stays an necessary distribution hub. In fact, there are additionally some challenges for firms looking for a foothold within the U.S., Ørnskov mentioned: "The bar for aesthetic merchandise approval is the best within the U.S. - by far the best - and it's grow to be even harder... but it surely's such an necessary market that now we have to do no matter it takes." Contact CEO Day by day through Diane Brady at [email protected] High management information. Do CEOs really matter? The Pulitzer Prize-winner creator of Weapons, Germs, and Metal examines that query in his forthcoming ebook. In an excerpt from Income, Prophets, Coaches, and Kings, Jared Diamond explains that CEOs have extra discretion in sure industries, resembling computer systems, cleaning soap and fragrance, video games and toys, movement footage, and clothes for younger individuals. However CEOs have much less discretion in public utilities, metal, shipbuilding, railways, and gasoline transmission. OpenAI limits entry to Astra's high cyber instruments OpenAI's Astra is considerably extra succesful than its present frontier AI mannequin, GPT-5.6 Sol, which itself is extremely succesful at cyber duties. However solely a handful of companions will get entry to its most superior cybersecurity capabilities as OpenAI works to stability serving to firms stop cyberattacks whereas not empowering attackers on the similar time. New invoice would tax AI tokens to fund jobs A brand new Home proposal would impose an excise tax on main AI firms and robotically improve the levy if unemployment climbs, funneling the cash into creating jobs in areas from housing development and infrastructure to youngster and elder care. The invoice proposes a bifurcated taxation: both tax the worth of the tokens or tax income from AI providers and sure transactions with affiliated firms, whichever yields the upper sum. The markets. S&P 500 futures are down 0.25% this morning. The STOXX Europe 600 was down 0.63% in early buying and selling. The U.Okay.'s FTSE 100 was down 0.52% in early buying and selling. The Nikkei 225 was down 2.85%. South Korea's KOSPI was down 3.99%. China's CSI 300 was down 1.38%. Hong Kong's Hold Seng was down 0.07%. India's NIFTY 50 was down 0.72%. Bitcoin is down at $77k. Across the watercooler. The Pentagon is giving 3 million navy and civilian employees entry to ChatGPT and Grok by a safe AI platform constructed for 'warfighter wants' by Marco Quiroz-Gutierrez IKEA is spending $1.4 billion to chop costs, becoming a member of Walmart and Goal in a race to win again customers by Mia Osmonbekov As soon as a champion for bodily media, Sony is now telling PlayStation clients they don't really personal the digital video video games they paid $70 for by Sasha Rogelberg As Gen Z flocks again to accounting, EY is investing $100 million in bonuses for workers who show they've human abilities by Preston Fore From a Singapore airport soundtrack to new AI-powered PCs, HP is on the lookout for a brand new rhythm in Asia by Angelica Ang CEO Day by day is curated and edited by Joseph Abrams, Jason Ma, Claire Zillman, and Lee Clifford.
Swiss dermatology company Galderma announced it will invest more than $650 million in US manufacturing through 2030. The company, which makes skincare brands including Cetaphil and injectable fillers like Sculptra, generated $5.24 billion in revenue last year, with the US accounting for 40% of sales and representing its fastest-growing market. CEO Flemming Ørnskov relocated the company's business from Fort Worth to Boston to access research and development talent. Galderma established its US headquarters in Miami as a gateway to Latin America and built a presence in Orange County, California, citing concentrated aesthetic expertise there. The investment reflects a broader trend of European companies increasing foreign direct investment in the US, which rose by $266 billion to $5.86 trillion in 2025, with manufacturing remaining the largest target sector.
Galderma's Relfydess(TM)(RelabotulinumtoxinA) receives positive decision for use in Europe. 1 5 minutes read * Relfydess(TM)(RelabotulinumtoxinA) is the first and only ready-to-use liquid neuromodulator created with PEARL(TM) Technology, developed and manufactured by Galderma[1,2] * This positive decision is based on results from the phase III READY clinical trial program, which showed that Relfydess(TM) delivered sustained results for six months, combined with an onset of action as early as day one, for both frown lines and crow's feet[3-8] * Galderma is committed to developing and delivering the broadest portfolio in Injectable Aesthetics * Once national approvals have taken place, Relfydess(TM) will be the first neuromodulator in Europe to receive initial approval for two indications - frown lines and crow's feet - at the same time * Relfydess(TM) also received marketing authorization from Australia's Therapeutic Goods Administration in June this year Galderma today announced that it has completed its European decentralized procedure (DCP), resulting in a positive decision for Relfydess(TM)(RelabotulinumtoxinA - previously referred to as QM1114). Relfydess(TM) is indicated for the temporary improvement in the appearance of moderate-to-severe glabellar lines (frown lines) at maximum frown and lateral canthal lines (crow's feet) seen at maximum smile, alone or in combination, in adult patients under 65 years, when the severity of these lines has an important psychological impact on the patient.[9] Following the successful completion of the DCP, national approvals in the 16 concerned countries are now under finalization. Relfydess(TM) also received a marketing authorization in Australia earlier this year. Subscribing To Digital Newspaper Outlets Discover more Booking Historical Guided Tours Shopping For Authentic South Asian Apparel Ordering Custom Business Printing Relfydess(TM) is developed and manufactured by Galderma. It is the first and only ready-to-use liquid neuromodulator created with PEARL(TM) Technology that is designed to preserve molecule integrity to deliver a highly active, innovative, complex-free molecule, with up to 39% of patients seeing effects from day one and up to 75% of patients maintaining improvements for six months for frown lines and crow's feet.[3,4,7,8] It is optimized for simple volumetric dosing, without reconstitution, to increase ease of use and help ensure consistent dose/volume.[1,10] | "With Relfydess(TM), Galderma is introducing a highly differentiated and innovative neuromodulator, reinforcing our leadership and strong growth in this field, and our commitment to developing and delivering the broadest portfolio in Injectable Aesthetics. As per the decentralized European approach, our teams are now finalizing the approval procedures at the country level, so we're ready to launch in multiple markets early next year." Discover more Sourcing Heavy Commercial Machinery pen drive Discovering Smart Home Gadgets FLEMMING ØRNSKOV, M.D., MPH, CHIEF EXECUTIVE OFFICER GALDERMA | This positive decision, and the previous Therapeutic Goods Administration approval in Australia, were based on results from the phase III READY (RElabotulinumtoxin Aesthetic Development StudY) clinical trial program, which enrolled more than 1,900 participants. Results showed:[3,4,7,8] * Improvement in both frown lines and crow's feet versus placebo: * In READY-1 and READY-2, treatment with Relfydess(TM) demonstrated a 96.3% none-or-mild responder rate for frown lines and 87.2% for crow's feet, after one month, vs 4.5% and 11.9% for placebo, respectively. * Onset of action as soon as day one: * In READY-1 and READY-2, 39% of patients reported improvements for frown lines and 34% reported improvements for crow's feet from day one. * Sustained results for six months: * In READY-1 and READY-2, up to 75% of patients maintained improvements for six months. * At month one, up to 96% achieved none-or-mild frown lines and crow's feet, which was sustained for six months in almost a quarter of patients. * Patient satisfaction was maintained for six months following treatment. | Discover more Downloading Interactive Geographic Maps Exploring Mobile And Wireless Accessories Tracking Latest Company News Updates "With the growing need for new innovations in the neuromodulator space, I'm excited that, with Relfydess(TM), we have a new treatment that delivers both fast and sustained results in a simple and convenient formulation, so we can achieve the desired outcomes for our patients quickly, effectively, and without compromise." DR. SACHIN SHRIDHARANI LEAD INVESTIGATOR OF READY-1 TRIAL PLASTIC SURGEON AND FOUNDER OF LUXURGERY | Regulatory applications for Relfydess(TM) for the treatment of frown lines and crow's feet will continue to be submitted and assessed by additional authorities globally. Streamlining Operations Software For Business About Relfydess(TM)(RelabotulinumtoxinA) Pioneered by Galderma, Relfydess(TM) is the first and only ready-to-use liquid neuromodulator created with PEARL(TM) Technology that is designed to preserve molecule integrity.[1,2] PEARL(TM) Technology is designed to deliver a highly active, innovative, complex-free molecule, with up to 39% of patients seeing effects from day one and up to 75% of patients maintaining improvements for six months.[1-4,7,8] Relfydess(TM) is optimized for simple volumetric dosing, without reconstitution, to increase ease-of-use and help ensure consistent dose/volume every time.[1,10] It was entirely developed and manufactured by Galderma to expand its neuromodulator portfolio as part of the broadest Injectable Aesthetics portfolio on the market. Booking Historical Guided Tours About the READY clinical trial program The READY (RElabotulinumtoxin Aesthetic Development StudY) phase III clinical program is composed of four phase III clinical trials which enrolled more than 1,900 participants.[3-6] The READY trials investigated the safety, efficacy, rapidity of onset and/or durability of Relfydess(TM) for six months on: * Frown lines (READY-1).[3] * Crow's feet (READY-2).[4] * Frown lines and crow's feet when treated alone or simultaneously (READY-3).[5] * Frown lines and crow's feet when treated alone or simultaneously with up to four repeated injections over 52 weeks (READY-4).[6] About Galderma Galderma (SIX: GALD) is the emerging pure-play dermatology category leader, present in approximately 90 countries. Mangaloremirror deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since its foundation in 1981, Mangaloremirror has dedicated its focus and passion to the human body's largest organ - the skin - meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because Mangaloremirror understand that the skin Mangaloremirror is in shapes its lives, Mangaloremirror is advancing dermatology for every skin story. For more information: www.galderma.com. References: * Sundberg AL and Stahl U. Relabotulinum toxin - a novel, high purity BoNT-A1 in liquid formulation. Presented at: TOXINS 2021; Jan 16-17, 2021; virtual meeting * Do M, et al. Purification process of a complex-free highly purified botulinum neurotoxin type A1 (BoNT-A1) - relabotulinumtoxinA. Presented at: TOXINS 2022; July 27-30, 2022; New Orleans, LA * Galderma. Data on file. Clinical Study Report for Protocol 43QM1602: READY-1. Galderma Laboratories; 2021 * Galderma. Data on file. Clinical Study Report for Protocol 43QM1901: READY-2. Galderma Laboratories; 2021 * Galderma. Data on file. Clinical Study Report for Protocol 43QM1902: READY-3. Galderma Laboratories; 2021 * Galderma. Data on file. Clinical Study Report for Protocol 43AM1903: READY-4. Galderma Laboratories; 2021 * Shridharani SM, et al. Efficacy and Safety of RelabotulinumtoxinA, a New Ready-to-Use Liquid Formulation Botulinum Toxin: Results From the READY-1 Double-Blind, Randomized, Placebo-Controlled Phase 3 Trial in Glabellar Lines. Aesthetic Surgery Journal. 2024; sjae131 * Ablon G, et al. Treatment of Lateral Canthal Lines with RelabotulinumtoxinA, an Investigational Liquid Botulinum Toxin: Clinical Efficacy and Safety Results from the READY-2 Phase III Trial. Abstract presented at TOXINS 2024; Jan 17-20, 2024, Berlin * Relfydess(R) EU Summary of Product Characteristics * Persson C, et al. Patient and Investigator Treatment Experience with Ready-to-Use AbobotulinumtoxinA Solution Versus Powder BotulinumtoxinA for Treatment of Glabellar Lines. Abstract presented at TOXINS 2024; Jan 17-20, 2024, Berlin
Galderma invests in Miami headquarters to expand U.S. Market presence. Aug 25th, 2026 On August 24, 20206, pure-play dermatology category leader Galderma announced the official opening of its U.S. and Latin America headquarters in Miami, establishing a new operational center for its U.S. business. Galderma says the new hub will support its U.S. and Latin American operations, with a dedicated injection room for hands-on training and education for healthcare professionals. Galderma also plans to grow its Miami workforce to roughly 200 employees, reflecting the company's continued investment in the United States and marking another milestone in Galderma's long-term growth strategy. The company says Miami was chosen because the market is a strong hub for dermatological skincare, aesthetics, and consumer health, aligning closely with Galderma's U.S. ambitions. Miami also offers robust connectivity across the U.S. and Latin America, positioning it well to support Galderma's expanding business and strengthen relationships with healthcare professionals, partners, and customers across both regions. "As our largest market, the United States is central to Galderma's long-term growth. This investment reflects our confidence in its continued expansion and our ambition to build Galderma into a dermatology powerhouse, scientifically, commercially, and operationally. By bringing key members of our U.S. and Latin America leadership teams together in Miami, we are creating a strategic hub that strengthens collaboration and enables us to execute our Integrated Dermatology Strategy with even greater impact," said Galderma's Chief Executive Officer, Flemming Ørnskov. More importantly, the investment is another example of f the company's broader U.S. growth strategy. Galderma's reported $3.134 billion in first-half 2026 sales, up 24.6% year over year, while its Injectable Aesthetics business grew 12.1%. That combination of capital, training infrastructure and portfolio expansion could translate into more education opportunities, stronger provider engagement and continued competition for share of the rapidly evolving medical aesthetics market. "Our new headquarters reflects how we want to work - bringing together expertise from across the business so teams can collaborate more effectively and move with greater agility. It strengthens our ability to execute on our strategy while supporting Galderma's continued growth in the United States," said Silvina Nordenstohl, who is the AD Interim for Galderma in the U.S.